Abstract
We previously reported that antiestrogen-liganded estrogen receptor β (ERβ) transcriptionally activates the major detoxifying enzyme quinone reductase (QR) (NAD(P)H:quinone oxidoreductase). Further studies on the functional role of ERβ-mediated upregulation of antioxidative enzymes indicated protective effects against estrogen-induced oxidative DNA damage (ODD). We now report on in vivo and in vitro studies that show that ERβ-mediated upregulation of QR are involved in the protection against estrogen-induced mammary tumorigenesis. Using the August Copenhagen Irish (ACI) model of estrogen-induced carcinogenesis, we observed that increased ODD and decreased QR expression occur early in the process of estrogen-induced mammary tumorigenesis. Prevention of ACI mammary gland tumorigenesis by tamoxifen was accompanied by decreased ODD and increased QR levels. These correlative findings were supported by our findings that downregulation of QR levels led to increased levels of estrogen quinone metabolites and enhanced transformation potential of 17β-estradiol treated MCF10A non-tumorigenic breast epithelial cells. Concurrent expression of ERβ and treatment with 4-hydroxytamoxifen decreased tumorigenic potential of these MCF10A cells. We conclude that upregulation of QR, through induction by tamoxifen, can inhibit estrogen-induced ODD and mammary cell tumorigenesis, representing a possible novel mechanism of tamoxifen prevention against breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- COMT:
-
catechol-O-methyltransferase
- E2:
-
17β-estradiol
- ER:
-
estrogen receptor
- ERα:
-
estrogen receptor α
- ERβ:
-
estrogen receptor β
- GST-Pi:
-
glutathione S-transferase Pi
- ODD:
-
oxidative DNA damage
- QR or NQO1:
-
quinone reductase
- siRNA:
-
short interfering RNAs
- TAM:
-
tamoxifen
- TOT:
-
4-hydroxytamoxifen
References
Ansell PJ, Espinosa-Nicholas C, Curran EM, Judy BM, Philips BJ, Hannink M et al. (2004). In vitro and in vivo regulation of antioxidant response element-dependent gene expression by estrogens. Endocrinology 145: 311–317.
Bianco NR, Perry G, Smith MA, Templeton DJ, Montano MM . (2003). Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced DNA damage. Mol Endocrinol 17: 1344–1355.
Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR . (1996). MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 148: 313–319.
Guo M, Joiakim A, Dudley DT, Reiners JJ . (2001). Suppression of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated CYP1A1 and CYP1B1 induction by 12-O-tetradecanoylphorbol-13-acetate: role of transforming growth factor beta and mitogen-activated protein kinases. Biochem Pharmacol 62: 1449–1457.
Harvell DM, Strecker TE, Tochacek M, Xie B, Pennington KL, McComb RD et al. (2000). Rat strain-specific actions of 17beta-estradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. Proc Natl Acad Sci USA 97: 2779–2784.
Helbock HJ, Beckman KB, Ames BN . (1999). 8-Hydroxydeoxyguanosine and 8-hydroxyguanine as biomarkers of oxidative DNA damage. Methods Enzymol 300: 156–166.
Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W et al. (2000). Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 27: 95–112.
Jones SB, Brooks JD . (2006). Modest induction of phase 2 enzyme activity in the F-344 rat prostate. BMC Cancer 6: 62–70.
Kassie F, Uhl M, Rabot S, Grasl-Kraupp B, Verkerk R, Kundi M et al. (2003). Chemoprevention of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ)-induced colonic and hepatic preneoplastic lesions in the F344 rat by cruciferous vegetables administered simultaneously with the carcinogen. Carcinogenesis 24: 255–261.
Li JJ, Papa D, Davis MF, Weroha SJ, Aldaz CM, El-Bayoumy K et al. (2002a). Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: comparison to invasive human ductal breast cancer. Mol Carcinog 33: 56–65.
Li SA, Weroha SJ, Tawfik O, Li JJ . (2002b). Prevention of solely estrogen-induced mammary tumors in female aci rats by tamoxifen: evidence for estrogen receptor mediation. J Endocrinol 175: 297–305.
Liehr JG . (2000). Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 21: 40–54.
Matusheski NV, Jeffery EH . (2001). Comparison of the bioactivity of two glucoraphanin hydrolysis products found in broccoli, sulforaphane and sulforaphane nitrile. J Agric Food Chem 49: 5743–5749.
Montano MM, Deng H, Liu M, Sun X, Singal R . (2004). Transcriptional regulation by the estrogen receptor of antioxidative stress enzymes and its functional implications. Oncogene 23: 2442–2453.
Montano MM, Jaiswal AK, Katzenellenbogen BS . (1998). Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-alpha and estrogen receptor-beta. J Biol Chem 273: 25443–25449.
Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK et al. (2001). Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60: 759–767.
Rogan EG, Badawi AF, Devanesan PD, Meza JL, Edney JA, West WW et al. (2003). Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 24: 697–702.
Saji S, Jensen EV, Nilsson S, Rylander T, Warner M, Gustafsson JA . (2000). Estrogen receptors and in the rodent mammary gland. Proc Natl Acad Sci USA 97: 337–342.
Thomas RD, Green MR, Wilson C, Weckle AL, Duanmu Z, Kocarek TA et al. (2006). Cytochrome P450 expression and metabolic activation of cooked food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in MCF10A breast epithelial cells. Chem Biol Interact 160: 204–216.
Acknowledgements
We thank Dr Sara Li (University of Kansas) for some of the ACI rat tissues, Dr Anil Jaiswal (Baylor College of Medicine) for the pMT2-QR vector and Dr Alan Wolfman (Lerner Research Institute, Cleveland Clinic) for Ha-RAS expression vector. This work was supported by the National Institute of Health Grants CA80959 and CA92440 to MMM, P01-CA49210 from the NIH and DAMD17-03-01-0229 from the US Army Breast Cancer Research Program to EC and ER, and ES05022 from the NIH to SMS.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Montano, M., Chaplin, L., Deng, H. et al. Protective roles of quinone reductase and tamoxifen against estrogen-induced mammary tumorigenesis. Oncogene 26, 3587–3590 (2007). https://doi.org/10.1038/sj.onc.1210144
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210144
Keywords
This article is cited by
-
Antioxidant-mediated up-regulation of OGG1 via NRF2 induction is associated with inhibition of oxidative DNA damage in estrogen-induced breast cancer
BMC Cancer (2013)
-
Selective estrogen receptor modulator BC-1 activates antioxidant signaling pathway in vitro via formation of reactive metabolites
Acta Pharmacologica Sinica (2013)
-
The exonuclease activity of hPMC2 is required for transcriptional regulation of the QR gene and repair of estrogen-induced abasic sites
Oncogene (2011)
-
Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer
Breast Cancer Research and Treatment (2010)
-
hPMC2 is required for recruiting an ERβ coactivator complex to mediate transcriptional upregulation of NQO1 and protection against oxidative DNA damage by tamoxifen
Oncogene (2008)